
Swiss drugmaker Roche won clearance from Britain’s Competition and Markets Authority (CMA) on Monday for its planned US$4.3 billion takeover of gene therapy company Spark Therapeutics, while a similar US review continues.
Roche wants to buy US-based Spark to gain a foothold in gene therapy as well as add to its portfolio against hemophilia A, where the Basel-based company already has the treatment Hemlibra that is due to surpass US$1 billion sales this year.
Competition authorities have been scrutinizing the deal to ensure a Roche gene therapy-Hemlibra combination in the lucrative rare disease market would not give it an unfair advantage over rivals.
Britain’s competition agency came to the conclusion it would not, even as the US Federal Trade Commission (FTC) has yet to formally weigh in. The CMA said it had “cooperated closely” with the FTC.
“The CMA found that Spark is not the only supplier developing a gene therapy treatment and that its products are not currently considered to hold any particular clinical or commercial advantages over those being developed by other suppliers,” the CMA stated.
“The CMA therefore found that the deal between Roche and Spark would not negatively affect competition,” the CMA stated in a statement issued by the London Stock Exchange
Featured News
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
DOJ Opens Antitrust Probe of Google’s AI Partnership with Character.AI
May 22, 2025 by
CPI
Google’s Unbundling Offer Puts Korean Regulators in Tight Spot
May 22, 2025 by
CPI
Justice Department and FTC Warn Common Ownership Could Breach Antitrust Law
May 22, 2025 by
CPI
South Africa Approves Canal+ MultiChoice Deal
May 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros